The numbers behind the research underscore why new treatments are so urgently needed. According to China’s National Cancer Center, more than 1.06 million new lung cancer cases were recorded in 2022, with 733,300 deaths, making lung cancer the deadliest malignancy in the country. Non-small cell lung cancer (NSCLC) accounts for roughly 85 percent of those cases, and because most patients are diagnosed at advanced stages, the five-year survival rate remains below 18 percent. Surgery, radiotherapy, chemotherapy, immunotherapy and targeted therapy all carry substantial toxicities, and drug resistance erodes their effectiveness over time. Against this backdrop, the search for natural compounds with defined molecular targets has intensified.

Led by Xue Li and Fu Peng of Sichuan University, together with colleagues at Chengdu University of Traditional Chinese Medicine and other institutions, the research team systematically tested Gymconopin C against two human NSCLC cell lines, A549 and NCI-H1299. In cell viability assays, the compound achieved half-maximal inhibitory concentrations (IC50) of 5.642 micromolar at 24 hours and 2.767 micromolar at 48 hours in A549 cells, and 2.047 and 1.152 micromolar respectively in NCI-H1299 cells. Cisplatin, by comparison, required 18.230 and 9.902 micromolar in A549 cells over the same periods—meaning Gymconopin C was several times more effective at suppressing cancer cell proliferation. Colony formation assays confirmed that treated cells lost their ability to form new colonies, while wound-healing and Transwell experiments showed that migration and invasion through artificial basement membranes were sharply curtailed.

At the molecular level, the compound appeared to sabotage the metastatic machinery of the cancer cells. Epithelial-mesenchymal transition, or EMT, is the process by which tumor cells shed their epithelial identity and adopt the mobile, invasive characteristics of mesenchymal cells. Gymconopin C reversed the hallmark “cadherin switch,” reducing levels of N-cadherin and vimentin while restoring E-cadherin. It also strengthened intercellular junctions by increasing the tight-junction proteins ZO-1 and claudin-1, and it suppressed the matrix-degrading enzymes MMP-2 and MMP-7, which tumors use to chew through surrounding tissue.

Flow cytometry revealed a second mechanism of attack: cell cycle arrest. After Gymconopin C treatment, the fraction of A549 cells trapped in the G2 phase of the cell cycle surged from just over 9 percent to more than 51 percent at higher doses. The compound reduced expression of the G2 regulatory proteins CDC25C, cyclin B1 and CDK1, blocking the transition needed for cells to divide. Simultaneously, apoptosis rose markedly, with pro-death proteins Bax and cleaved caspase-3 climbing while the anti-apoptotic protein survivin declined.

But the most consequential discovery involved mitochondria. Transmission electron microscopy of treated cells revealed profound mitochondrial damage—dissolution of the cristae that house the machinery of cellular respiration—alongside numerous autophagic vesicles and autolysosomes. The compound was triggering mitophagy, the selective autophagic removal of damaged mitochondria. While moderate mitophagy helps tumor cells maintain their metabolism, excessive mitophagy can cause catastrophic bioenergetic collapse. When the researchers co-treated cells with Mdivi-1, a chemical inhibitor of mitophagy, the cancer-killing effect of Gymconopin C was substantially blunted—direct evidence that the compound works by pushing mitochondrial destruction past a lethal threshold.

The downstream consequences were consistent with this model. Gymconopin C-treated cells accumulated reactive oxygen species and mitochondrial superoxide, their mitochondrial membrane potential collapsed as measured by JC-1 staining, and both ATP production and mitochondrial DNA copy number fell significantly. Senescence-associated beta-galactosidase staining showed the cells entering a senescent state. Protein analysis confirmed activation of the canonical PINK1/Parkin mitophagy pathway: levels of LC3B-II, BNIP3, PINK1 and Parkin rose, while mitochondrial structural proteins TIM23, TOM20 and VDAC1—markers of surviving mitochondria—were depleted.

To identify how the compound initiates this cascade, the team turned to whole-transcriptome sequencing. Among 156 differentially expressed microRNAs, one stood out: hsa-miR-6777-5p, the most strongly downregulated miRNA after treatment. Database analyses using CancerMIRNome and dbDEMC showed that this miRNA is elevated in NSCLC and that high levels correlate with poorer survival, marking it as an oncogene. Molecular docking predicted that Gymconopin C binds directly to miR-6777-5p through hydrogen bonds and π-hydrogen interactions, with a favorable binding energy score of −5.3844 kcal/mol, suggesting the compound may physically occupy the miRNA’s functional domain and disable it.

The researchers then traced the pathway downstream. Cross-referencing predicted targets of miR-6777-5p from the miRDB, TargetScan and miRWalk databases with genes upregulated by the drug, they identified ADRB2—the beta-2 adrenergic receptor—as a key target. RNA immunoprecipitation experiments confirmed that miR-6777-5p binds ADRB2 messenger RNA via the Ago2 protein complex, and that suppressing the miRNA releases ADRB2 expression. Functional tests sealed the loop: overexpressing miR-6777-5p promoted cancer cell proliferation, migration and invasion while suppressing mitophagy, whereas knocking down ADRB2 had similar pro-tumor effects. Conversely, forcing ADRB2 expression halted proliferation and enhanced PINK1/Parkin-mediated mitophagy—an effect reversed by miR-6777-5p. Prior research had shown ADRB2 activation boosts LC3B and Parkin expression, and clinical data indicate low ADRB2 levels predict poor survival in lung adenocarcinoma, consistent with its role as a tumor suppressor here.

The in vivo results were equally compelling. In BALB/C nude mice bearing A549 xenograft tumors, daily intraperitoneal Gymconopin C at 18 mg/kg for 25 days significantly shrank tumor volume and weight, reduced the proliferation marker Ki-67 in tumor tissue, and elevated LC3B, Parkin and ADRB2 levels—mirroring the in vitro findings. Critically, the safety profile favored the natural compound. Mice receiving cisplatin lost weight, showed anorexia and reduced mobility, and suffered measurable spleen and kidney damage with elevated blood urea nitrogen. Gymconopin C-treated animals maintained stable body weight and normal organ architecture on histological examination, with liver and kidney function indicators indistinguishable from healthy controls.

A third model added an innovative dimension. The team transplanted fluorescently labeled human cancer cells into zebrafish larvae, a rapid and ethically lighter system for drug screening. Gymconopin C showed dose-dependent anti-tumor activity with a maximum tolerated dose of 100 ng per fish and an LD50 of 185 ng, demonstrating a wide therapeutic window. When the researchers engineered zebrafish tumors overexpressing miR-6777-5p, tumor cells proliferated aggressively—but Gymconopin C neutralized the effect, shrinking fluorescent tumor signals and reducing invasion. This confirmed in a living vertebrate that the miRNA is a genuine functional target of the drug.

The authors caution that the miR-6777-5p/ADRB2 axis was validated primarily in A549 cells, and that its generalizability across the molecularly diverse landscape of NSCLC subtypes—driven by mutations in EGFR, KRAS, ALK and ROS1—will require further study. The direct physical binding between the compound and the miRNA also remains a computational prediction pending biophysical confirmation. Even so, the study delivers something rare for a natural product: a complete mechanistic chain from chemical structure to molecular target to cellular pathway to animal efficacy, with safety data suggesting a therapeutic margin wider than that of standard platinum chemotherapy.

If subsequent development confirms these results, Gymconopin C could represent a new class of anti-cancer agents that weaponize mitophagy against tumors—and a vindication of traditional Chinese medicine as a source of structurally novel drugs with precisely defined mechanisms of action.

Immunotherapy, particularly the administration of immune checkpoint inhibitors targeting proteins such as PD-1 and CTLA-4, has transformed lung cancer outcomes, extending survival for many advanced-stage patients. However, the flip side of this success has been the emergence of immune-related adverse events (irAEs), which arise when immune activation intended to fight cancer spills over into normal tissues. Pneumonitis, characterized by inflammation of lung parenchyma, can dramatically impair respiratory function and, in severe cases, lead to respiratory failure. Despite its clinical significance, the precise immunopathological mechanisms behind immunotherapy-associated pneumonitis remain poorly understood, hindering the development of predictive biomarkers and targeted interventions.

The team, led by Lin, X., Li, C., and Deng, J., employed a multifaceted approach combining advanced single-cell transcriptomics, spatial profiling, and functional immunology assays on samples from lung cancer patients who developed pneumonitis post immunotherapy. Their analyses identified distinct populations of immune cells infiltrating lung tissue, including hyperactivated T lymphocytes with a pro-inflammatory phenotype and aberrantly activated macrophages, which together create a self-sustaining inflammatory milieu. Remarkably, these immune cells exhibited gene expression profiles suggestive of dysregulated checkpoint signaling and chronic activation, indicating that therapies designed to invigorate antitumor immunity may inadvertently unleash pathogenic immune circuits in the lung microenvironment.

Further mechanistic investigations revealed an intricate interplay between innate and adaptive immune players. The researchers pinpointed a subset of CD8+ cytotoxic T cells expressing elevated levels of granzyme B and perforin, molecules typically involved in killing tumor cells, now implicated in collateral damage to lung epithelial cells. Additionally, these effector T cells produced excessive pro-inflammatory cytokines such as interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α), which amplify local inflammation and recruit additional immune effectors. Complementing this, lung-resident macrophages shifted towards a pro-inflammatory M1-like phenotype, producing chemokines that attract neutrophils and amplify tissue injury, disrupting the delicate balance required for lung homeostasis.

The researchers also uncovered that the cytokine milieu in pneumonitis patients diverged significantly from those without this complication. Elevated levels of interleukin-6 (IL-6), interleukin-17 (IL-17), and other inflammatory mediators suggested that an exaggerated inflammatory feedback loop was a key driver of lung pathology. Intriguingly, this cytokine profile bore resemblance to autoimmune and hyperinflammatory syndromes, underscoring the complexity of immune dysregulation triggered by checkpoint inhibitors. This finding highlights the potential benefit of repurposing immunomodulatory therapies, such as corticosteroids or IL-6 receptor antagonists, to mitigate pneumonitis without compromising antitumor immunity.

One of the study’s critical contributions lies in the identification of potential biomarkers predictive of pneumonitis onset. By integrating patient clinical data with molecular and cellular signatures, the authors propose a composite risk score based on immune cell infiltration patterns and serum cytokine levels. This score could enable oncologists to stratify patients before commencing immunotherapy, screening for those at heightened risk, and adjusting treatment protocols accordingly. Such proactive measures are vital for minimizing serious toxicities while preserving the transformative benefits of immunotherapy.

The implications of these findings extend beyond pneumonitis to other immune-related adverse events that challenge immunotherapy’s wider applicability. The study’s comprehensive characterization of immune dysregulation offers a blueprint for dissecting tissue-specific toxicities, advancing toward personalized cancer immunotherapy. Moreover, understanding how immune checkpoint inhibition disturbs pulmonary immune homeostasis has ramifications for managing lung inflammation in settings such as infections, autoimmunity, and transplant rejection.

In a broader context, this research exemplifies the power of single-cell and spatial technologies in unraveling complex pathologies at a resolution previously unattainable. By mapping immune cell states and their interactions within the native lung microenvironment, the team illuminated the dynamic processes fueling immunotherapy-induced pneumonitis. Their approach could be adapted to investigate other toxicities or even tumor microenvironment remodeling during therapy, catalyzing precision oncology.

Notably, the researchers emphasize the need for longitudinal studies to monitor immune evolution during immunotherapy and better capture the temporal dynamics of pneumonitis development. Prospective integration of immune profiling in clinical trials will be crucial for validating biomarkers and intervention strategies. Additionally, delving deeper into genetic and environmental factors influencing susceptibility to pneumonitis could uncover novel prevention avenues.

This landmark study not only advances fundamental knowledge of immune checkpoint-related lung toxicity but also underscores the delicate equilibrium between therapeutic immune activation and pathological inflammation. Achieving this balance remains a formidable challenge but one with enormous clinical payoff potential. As immunotherapies continue to transform oncology, parallel efforts to elucidate and mitigate their collateral immune damage will be indispensable for maximizing patient benefit.

Moving forward, combining immunotherapy with targeted immune modulators informed by mechanistic insights holds promise for enhancing efficacy and safety simultaneously. For instance, transiently damping specific cytokine pathways or selectively inhibiting deleterious immune cell subsets during therapy could quell pneumonitis risk without blunting antitumor responses. Developing such nuanced regimens will require multidisciplinary collaboration among immunologists, clinicians, and computational biologists.

Ultimately, this seminal work spearheaded by Lin and colleagues exemplifies precision medicine’s promise—harnessing detailed immune profiling to tailor cancer treatment intricacies and minimize harms. As the oncology community embraces increasingly sophisticated biotechnologies, the frontier between curing cancer and preserving patient quality of life grows ever narrower. Robust mechanistic understanding of immunotherapy toxicities will be key to straddling this frontier successfully.

In conclusion, uncovering the immune mechanisms driving immunotherapy-induced pneumonitis marks a pivotal step toward safer immuno-oncology. The constellation of hyperactivated cytotoxic T cells, pro-inflammatory macrophages, and dysregulated cytokine networks revealed here provide critical targets for predicting, monitoring, and intervening in this severe adverse event. As immune checkpoint blockade expands its transformative reach, translating these findings into clinical practice promises to improve outcomes for lung cancer patients worldwide, balancing oncologic triumph with immune homeostasis. This research heralds a new era of integrated, mechanism-based management of immunotherapy toxicities, heralding a safer future for cancer immunotherapy.

Subject of Research: Immune mechanisms underlying immunotherapy-induced pneumonitis in lung cancer patients

Article Title: Uncovering the immune mechanisms underlying the emergence of immunotherapy-induced pneumonitis in lung cancer patients

Article References:

Lin, X., Li, C., Deng, J. et al. Uncovering the immune mechanisms underlying the emergence of immunotherapy-induced pneumonitis in lung cancer patients.
Nat Commun (2025). https://doi.org/10.1038/s41467-025-66509-x

Image Credits: AI Generated

This exploratory, randomized pilot study, conducted across multiple centers, sought to assess the safety and immunomodulatory effects of BJIKT—a well-known herbal remedy used traditionally in East Asian medicine for its anti-inflammatory and fatigue-relieving properties. The study specifically targeted patients with advanced NSCLC receiving atezolizumab monotherapy, an anti-PD-L1 checkpoint inhibitor widely used in clinical oncology. By integrating this herbal medicine with modern immunotherapy, the researchers aimed to explore if BJIKT could mitigate some common treatment-related adverse events such as fatigue and muscle wasting, while potentially enhancing immune activation.

The trial enrolled 28 patients who were randomly assigned to receive either BJIKT or a placebo, with both groups continuing standard atezolizumab therapy. Throughout the study, the team meticulously monitored adverse events (AEs), immune-related adverse events (irAEs), fatigue levels, and the progression of muscle loss, aiming to uncover interactions between the herbal treatment and immune checkpoint blockade. Beyond clinical symptomatology, a subset of patients underwent detailed immune profiling to shed light on the cellular immune mechanisms potentially influenced by BJIKT.

Findings revealed that adverse events were prevalent in over half of participants, a not unexpected outcome given the aggressive nature of cancer immunotherapy. Intriguingly, the BJIKT group exhibited a higher incidence of AEs (64.29%) compared to the placebo group (42.86%), though the majority of these events were mild to moderate and resolved by the conclusion of the trial. This raises important safety considerations but also underscores the complex interplay between herbal compounds and immune modulation therapies, warranting further pharmacovigilance in larger cohorts.

From an efficacy standpoint, the objective response rate (ORR) and disease control rate (DCR) were numerically higher in the BJIKT-treated group—16.67% versus 8.33% for ORR and 41.67% versus 25% for DCR compared to placebo—though these differences did not reach statistical significance. These encouraging trends suggest that BJIKT might augment tumor growth control during ICI therapy, possibly by enhancing the host immune system’s anti-tumor prowess. Nonetheless, the lack of statistical significance tempers overenthusiasm and highlights the exploratory nature of this pilot trial.

One of the more compelling aspects of the study lies in its immunological analyses. The researchers detected a significant reduction in PD-1 positive CD8+ T cells in patients receiving BJIKT, implying a decrease in T cell exhaustion—a state where T cells become less functional due to chronic antigen exposure, commonly seen in cancer. This finding indicates that BJIKT may reinvigorate cytotoxic T cells, a pivotal cell population responsible for directly attacking tumor cells. Conversely, while PD-1+ CD4+ T cell numbers also declined with BJIKT, this change was not statistically significant, suggesting a selective modulation of T cell subsets.

Beyond T cells, a notable increase in natural killer (NK) cell counts was observed in the BJIKT group. NK cells constitute an essential arm of innate immunity, capable of recognizing and destroying cancer cells without prior sensitization. The elevation of these effector cells may reflect enhanced innate immune surveillance facilitated by BJIKT, potentially contributing to improved tumor control in NSCLC. Moreover, immune profiling revealed trends toward increased activation of CD4+ T cells and the overall proportion of CD3+CD4+ cells, indicating a broader stimulation of helper T cell-mediated immune orchestration during treatment.

BJIKT’s capacity to alleviate fatigue and muscle loss—common debilitating symptoms experienced by patients undergoing immunotherapy—was also examined. While the herbal treatment showed a trend toward mitigating these symptoms, the changes were not statistically significant. Still, these observations correlate with BJIKT’s traditional use in managing fatigue and chronic inflammation, suggesting it may hold supportive care value for NSCLC patients in future integrative oncology frameworks.

The study’s design as a randomized, placebo-controlled pilot trial provides valuable preliminary insights but naturally comes with limitations inherent to small sample sizes, which restrict the statistical power to detect definitive effects. However, the findings lay a foundation for subsequent larger-scale investigations to validate BJIKT’s immunomodulatory benefits and safety profile in combination with ICIs. Such follow-up trials could also dissect the molecular pathways involved, potentially revealing novel complementary mechanisms by which traditional herbal medicine synergizes with cutting-edge immunotherapies.

Notably, the interplay between BJIKT and the complex tumor-immune microenvironment highlights the exciting potential of combining phytochemicals with immuno-oncological agents. This fusion of ancient herbal wisdom with modern molecular oncology could pave the way for innovative, multi-modal cancer treatment regimens aimed at boosting efficacy while minimizing toxicities. Furthermore, the selective immune effects observed with BJIKT—specifically the reduction of immune exhaustion markers and augmentation of NK cells—underscore the importance of immune homeostasis in achieving sustained anti-tumor responses.

From a clinical perspective, this research advocates for integrating complementary therapies like BJIKT into the multidisciplinary care of NSCLC patients receiving ICIs. Positive modulation of immune function and alleviation of adverse symptom burden could improve patient adherence to therapy and quality of life. However, the necessity for rigorous validation studies, standardized herbal preparations, and mechanistic elucidations cannot be overstated before broad application.

Additionally, the trial was registered with the Clinical Research Information Service of Korea, ensuring adherence to ethical and methodological standards. Such transparency not only bolsters credibility but also facilitates collaboration, data sharing, and global efforts to refine cancer therapies. Future studies may build upon this pilot trial to design adaptive, biomarker-driven approaches targeting immune exhaustion and enhancing effector cell function in NSCLC and beyond.

In summary, this pioneering research sheds light on the prospective role of Bojungikki-Tang as an adjunctive agent capable of finely tuning the immune landscape in NSCLC patients undergoing atezolizumab therapy. While conclusive evidence remains forthcoming, the reported reductions in immune exhaustion markers and elevations in innate immune effectors inspire optimism for harnessing herbal pharmacology in the fight against lung cancer. This convergence of traditional medicine and immuno-oncology represents a fertile frontier warranting enthusiastic scientific pursuit.

As the oncology community continues to grapple with the challenges of maximizing immunotherapy benefit, findings like these energize the search for integrative strategies. Bojungikki-Tang’s ancient formula, reinterpreted through the lens of modern immune profiling, exemplifies how history may inform future breakthroughs. Clinical trials with larger cohorts, longer follow-up, and multi-omics analyses will be imperative to validate these preliminary signals and ultimately translate them into robust, patient-centered cancer care innovations.

Subject of Research: Effects of Bojungikki-Tang on immune response and clinical outcomes in NSCLC patients receiving immune checkpoint inhibitors

Article Title: Effects of Bojungikki-Tang on immune response and clinical outcomes in NSCLC patients receiving immune checkpoint inhibitors: a randomized pilot study

Article References:
Ko, M.M., Na, S.W., Yi, J.M. et al. Effects of Bojungikki-Tang on immune response and clinical outcomes in NSCLC patients receiving immune checkpoint inhibitors: a randomized pilot study. BMC Cancer 25, 1229 (2025). https://doi.org/10.1186/s12885-025-14629-4

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14629-4